DrugPatentWatch Database Preview

Details for Patent: 9,364,564

Which drugs does patent 9,364,564 protect, and when does it expire?

Patent 9,364,564 protects CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, and CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, and is included in one NDA.

This patent has twenty-three patent family members in eleven countries.

Summary for Patent: 9,364,564

Title:	Pre-mixed, ready-to-use pharmaceutical compositions
Abstract:	Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
Inventor(s):	Duncan; Michelle Renee (Glenview, IL), Gupta; Supriya (Sunnyvale, CA), Haas; David Hartley (Fremont, CA), Stephens; Norma V. (Skokie, IL), Zamiri; Camellia (Fremont, CA)
Assignee:	EKR Therapeutics, Inc. (Cary, NC)
Application Number:	12/645,169
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 9,364,564

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Chiesi Usa Inc	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-004	Nov 7, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Chiesi Usa Inc	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-003	Jul 31, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Chiesi Usa Inc	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-002	Jul 31, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Chiesi Usa Inc	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-005	Nov 7, 2008		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 9,364,564

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,455,524	Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions	➤ Sign Up
9,549,994	Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin	➤ Sign Up
7,612,102	Pre-mixed, ready-to-use pharmaceutical compositions	➤ Sign Up
9,370,586	Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 9,364,564

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
South Korea	20090037388	➤ Sign Up
South Korea	20090040258	➤ Sign Up
Mexico	2008013405	➤ Sign Up
Mexico	2008013407	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 9,364,564

For more information try a trial or see the plans and pricing